ClinicalTrials.gg
CompletedNCT05803421ACHIEVE-4Updated Apr 17, 2026

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

A Phase 3 interventional study of Orforglipron and Insulin Glargine in Type 2 Diabetes, Obesity and Overweight or Obesity, sponsored by Eli Lilly and Company. Completed at 358 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,749
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.

Enrollment
Largest of 15
2,749 · median 546
Started
2023
with 5 others
Phase 3
11 of 15
2 open now
Registered
4th of 15
by date
Lead sponsor
14 of 15
Eli Lilly and Company

Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About orforglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing orforglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

03

Conditions studied

  • Type 2 Diabetes
  • Obesity
  • Overweight or Obesity
  • Overweight
  • Cardiovascular Diseases
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with type 2 diabetes mellitus (T2DM)
  • Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
  • Have at screening

    • ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or
    • ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.
  • Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
  • Have increased risk for cardiovascular (CV) events due to:

    • Coronary heart disease
    • Peripheral arterial disease, presumed to be of atherosclerotic origin
    • Cerebrovascular disease, presumed to be of atherosclerotic origin
    • Chronic kidney disease (CKD)
    • Congestive heart failure (CHF) (NYHA) functional classification II to III
  • Are of stable weight (± 5%) for at least 90 days prior to screening
  • Have a ≥25 kilograms per meter squared (kg/m2) at screening

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have had chronic or acute pancreatitis any time prior to screening
  • Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors
  • Have a known gastric emptying abnormality
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the (ULN) for the reference range, as determined by the central laboratory
  • Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure
  • Have an \<15 mL/min/1.73 m2 as determined at screening
  • Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days
  • Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,749 participants (actual)

Study arms

  • Experimental
    Orforglipron

    Participants will receive escalated doses of orforglipron orally.

    Drug: Orforglipron

  • Active comparator
    Insulin Glargine

    Participants will receive insulin glargine subcutaneously (SC). Doses will be individualized and titrated according to a treat-to-target algorithm.

    Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]

    Time to First Occurrence of Any MACE-4 (Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular \[CV\] Death)

    Time frame: Baseline to End of the Study (Approximate Maximum 104 Weeks)

Secondary outcomes

  1. Time to First Occurrence of Any MACE-3 Event (MI, Stroke, or CV death)

    Time to First Occurrence of Any MACE-3 Event (MI, Stroke, or CV death)

    Time frame: Baseline to End of the Study (Approximately 104 Weeks)

  2. Change from Baseline in Hemoglobin A1c (HbA1c)

    Change from Baseline in HbA1c

    Time frame: Baseline, Week 52

  3. Change from Baseline in Fasting Serum Glucose

    Change from Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 52

  4. Change from Baseline in Daily Average 7-point Self-monitoring Blood Glucose (SMBG) Profile

    Change from Baseline in Daily Average 7-point SMBG

    Time frame: Baseline, Week 52

  5. Percentage of Participants with HbA1c Target Values Less Than (<)7.0% (53 mmol/mol)

    Percentage of Participants with HbA1c Target Values \<7.0% (53 mmol/mol)

    Time frame: Week 52

  6. Change from Baseline in Body Weight

    Change from Baseline in Body Weight

    Time frame: Baseline, Week 52

  7. Percent Change from Baseline Body Weight

    Percent Change from Baseline Body Weight

    Time frame: Week 52

  8. Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Score

    The SF-36v2 acute form is a 36-item generic, participant completed measure designed to assess 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Scores of each domain are measured by T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health.

    Time frame: Baseline, Week 52

  9. Pharmacokinetics (PK): Plasma Serum Concentrations of Orforglipron

    PK will be estimated based on the population PK model.

    Time frame: Baseline through Week 52

07

Study locations

358 sites
  • Alliance for Multispecialty Research, LLC
    Daphne, Alabama 36526, United States
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Cahaba Research - Pelham
    Pelham, Alabama 35124, United States
  • Syed Research Consultants Llc
    Sheffield, Alabama 35660, United States
  • The Institute for Liver Health
    Chandler, Arizona 85224, United States
  • Aventiv Research
    Mesa, Arizona 85206, United States
  • Arizona Liver Health - Peoria
    Peoria, Arizona 85381, United States
  • Elite Clinical Studies, LLC
    Phoenix, Arizona 85018, United States
  • Absolute Clinical Research
    Phoenix, Arizona 85051, United States
  • Clinical Research Institute of Arizona (CRI) - Sun City West
    Sun City West, Arizona 85375, United States
  • Alliance for Multispecialty Research, LLC
    Tempe, Arizona 85281, United States
  • Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • KLR Business Group, Inc. dba Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Hope Clinical Research, Inc.
    Canoga Park, California 91303, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • Neighborhood Healthcare Institute of Health
    Escondido, California 92025, United States
  • Valley Research
    Fresno, California 93720, United States
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Velocity Clinical Research, Los Angeles
    Los Angeles, California 90017, United States
  • Infinity Clinical Research - Norco
    Norco, California 92860, United States
  • Velocity Clinical Research, North Hollywood
    North Hollywood, California 91606, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • LCGK Research
    San Carlos, California 94070, United States
  • Norcal Endocrinology & Internal Medicine
    San Ramon, California 94583, United States
  • Velocity Clinical Research, Coastal Heart Medical Group
    Santa Ana, California 92704, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Millennium Clinical Trials
    Westlake Village, California 91361, United States
  • Rocky Mountain Regional VA Medical Center
    Aurora, Colorado 80045, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Legacy Clinical Trials
    Colorado Springs, Colorado 80909, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Orlando Heart & Vascular Institute
    Altamonte Springs, Florida 32714, United States
  • JEM Research Institute
    Atlantis, Florida 33462, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Velocity Clinical Research, New Smyrna Beach
    Edgewater, Florida 32132, United States
  • Alliance for Multispecialty Research, LLC
    Fort Myers, Florida 33912, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Nature Coast Clinical Research - Inverness
    Inverness, Florida 34452, United States
  • Northeast Research Institute - Downtown Office
    Jacksonville, Florida 32204, United States
  • Clinical Research of Central Florida
    Lakeland, Florida 33805, United States
  • Clinical Site Partners Leesburg
    Leesburg, Florida 34748, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Adult Medicine of Lake County
    Mt. Dora, Florida 32757, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Better Life Clinical Research
    Tampa, Florida 33607, United States
  • Precision Research Center
    Tampa, Florida 33614, United States
  • Care Access - Tampa
    Tampa, Florida 33625, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Conquest Research
    Winter Park, Florida 32789, United States
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia 30046, United States
  • The Jones Center Clinical Research
    Macon, Georgia 31210, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Saltzer Health
    Nampa, Idaho 83686, United States
  • Elite Clinical Trials
    Rexburg, Idaho 83440, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • Midwest CRC
    Crystal Lake, Illinois 60012, United States
  • AMR Clinical
    Oak Brook, Illinois 60523, United States
  • NorthShore University Health System
    Skokie, Illinois 60077, United States
  • American Health Network of Indiana, LLC - Avon
    Avon, Indiana 46123, United States
  • Investigators Research Group
    Brownsburg, Indiana 46112, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • American Health Network of Indiana, LLC - Franklin
    Franklin, Indiana 46131, United States
  • American Health Network of Indiana, LLC - Greenfield
    Greenfield, Indiana 46140, United States
  • American Health Network of Indiana, LLC - Muncie
    Muncie, Indiana 47304, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • Cotton O'Neil Mulvane
    Topeka, Kansas 66606, United States
  • Qualmedica Research
    Bowling Green, Kentucky 42101, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Louisiana Heart Center - Convington
    Covington, Louisiana 70433, United States
  • Care Access - Lake Charles (Bayou Pines)
    Lake Charles, Louisiana 70601, United States
  • Alliance for Multispecialty Research, LLC
    New Orleans, Louisiana 70119, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Endocrine and Metabolic Consultants
    Rockville, Maryland 20852, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Revival Research Institute
    Dearborn, Michigan 48126, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • SKY Clinical Research Network Group - Hall
    Fayette, Mississippi 39069, United States
  • SKY Integrative Medical Center/SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Diabetes and Endocrinology Specialists
    Chesterfield, Missouri 63017, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65807, United States
  • Logan Health Research
    Kalispell, Montana 59901, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States

Showing the first 100 of 358 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Mar 2026, 35 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 35 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 7, 2023
StartActual
Apr 3, 2023
Primary completionActual
Mar 16, 2026
CompletionActual
Mar 16, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05803421
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Apr 3, 2023
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
Apr 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion